Rhythm Pharmaceuticals, Inc. Share Price
NASDAQ: RYTM | Mid CapRhythm Pharmaceuticals, Inc. Stock Performance
Open $113.18 | Prev. Close $111.93 | Circuit Range N/A |
Day Range $111.95 - $116.06 | Year Range $74.51 - $122.00 | Volume 36,015 |
Average Traded $114.27 |
Rhythm Pharmaceuticals, Inc. Share Price Today
As of 10 August 2026, Rhythm Pharmaceuticals, Inc.'s share price is $115.67. The stock opened at $113.18, compared to its previous close of $111.93. During today's trading session, Rhythm Pharmaceuticals, Inc.'s share price traded between $111.95 and $116.06, with an average price of $114.01. Over the past 52 weeks, the stock has recorded a high of $122.00 and a low of $74.51. In terms of performance, Rhythm Pharmaceuticals, Inc.'s share price has risen by 24.61% over the last six months and is up 12.03% on a year-on-year basis.
Rhythm Pharmaceuticals, Inc. Share Price Chart
Rhythm Pharmaceuticals, Inc. Stock Fundamentals & Key Indicators
Market Cap $7.52B | PE Ratio (TTM) -37.19 | Dividend Yield 0.07% |
EPS (TTM) $-3.11 | Revenue (TTM) $189.76M | Return On Equity (TTM) -141.32% |
Profit Margin -103.57% | Debt to Equity 0.76 | Quarterly Earnings Growth YoY -21.23% |
Rhythm Pharmaceuticals, Inc. Quarterly Profit & Loss
All figures in USD
Rhythm Pharmaceuticals, Inc. Annual Profit & Loss
All figures in USD
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
Rhythm Pharmaceuticals, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $100.39 | $115.67 | +16.53% |
Jul 2026 | $113.03 | $99.27 | -10.52% |
Jun 2026 | $87.60 | $110.93 | +25.54% |
May 2026 | $81.28 | $88.36 | +8.48% |
Apr 2026 | $88.03 | $81.45 | -6.38% |
Mar 2026 | $90.18 | $87.00 | -6.28% |
Feb 2026 | $105.28 | $92.83 | -9.46% |
Jan 2026 | $107.08 | $102.53 | -4.29% |
Dec 2025 | $107.91 | $107.13 | -1.81% |
Nov 2025 | $113.88 | $109.11 | -4.24% |
Oct 2025 | $101.31 | $113.94 | +12.76% |
Sep 2025 | $103.38 | $101.05 | -2.13% |
RYTM Share Price FAQs
What is Rhythm Pharmaceuticals, Inc. share price today?
What is the 52 week high and 52 week low of Rhythm Pharmaceuticals, Inc. stock?
What is RYTM's market capitalisation today?
What is RYTM's net income for the last quarter?
What is the 5 year returns of RYTM?
What is the high & low stock price of RYTM today?
Can I buy RYTM shares in India?